Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma

被引:47
|
作者
Arabi, Mohammad [1 ]
BenMousa, Ali [2 ]
Bzeizi, Khaled [2 ]
Garad, Fares [1 ]
Ahmed, Ishtiaq [1 ]
Al-Otaibi, Melfi [2 ]
机构
[1] Prince Sultan Mil Med City, Dept Med Imaging, Div Intervent Radiol, Riyadh 11159, Saudi Arabia
[2] Prince Sultan Mil Med City, Dept Hepatol, Riyadh 11159, Saudi Arabia
来源
SAUDI JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 03期
关键词
Conventional transarterial chemoembolization; drug-eluting beads; hepatocellular carcinoma; RANDOMIZED PHASE-II; ARTERIAL CHEMOEMBOLIZATION; DEB-TACE; LIPIODOL; TRIAL; GUIDELINES; SAFETY;
D O I
10.4103/1319-3767.157571
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: To compare the efficacy and safety profile of doxorubicin-loaded drug-eluting beads (DEB) to the conventional TACE (C-TACE) in the management of nonresectable hepatocellular carcinoma (HCC). Patients and Methods: All patients with nonresectable HCC who underwent either c-TACE or DEB-TACE during the period 2006-2014 and fulfilled the inclusion criteria were included in this retrospective study. Primary endpoints were tumor response rate at first imaging follow up, treatment-related liver toxicity, and treatment emergent adverse events (TEAE). Results: Thirty-five patients (51 procedures) in the DEB-TACE group and 19 patients (25 procedures) in the c-TACE group were included in the analysis. The median follow up time was 61 days (range 24-538 days) in the DEB-TACE group and 86 days (range 3-152 days) for the c-TACE group patients. Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group. Mean ALT change from baseline was minimal in the DEB-TACE patients compared with c-TACE group (7.2 vs 79.4 units, P = 0.001). Hospital stay was significantly shorter in the DEB-TACE group (7.8 days vs 11.4 days; P = 0.038). The 2-year survival rate was 60% for the c-TACE patients and 58% for the DEB-TACE (P = 0.4). Conclusions: DEB-TACE compared with c-TACE is associated with lesser liver toxicity benefit, better tolerance, and shorter hospital stay. The two modalities however had similar survival and efficacy benefits.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [21] CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study
    Wu, Baolin
    Zhou, Jun
    Ling, Gonghao
    Zhu, Dongyong
    Long, Qingyun
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [22] Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
    Ren, Yanqiao
    Guo, Yusheng
    Chen, Lei
    Sun, Tao
    Zhang, Weihua
    Sun, Bo
    Zhu, Licheng
    Xiong, Fu
    Zheng, Chuansheng
    CANCER CONTROL, 2022, 29
  • [23] Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
    Facciorusso, Antonio
    Di Maso, Marianna
    Muscatiello, Nicola
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 571 - 577
  • [24] A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
    van Malenstein, Hannah
    Maleux, Geert
    Vandecaveye, Vincent
    Heye, Sam
    Laleman, Wim
    van Pelt, Jos
    Vaninbroukx, Johan
    Nevens, Frederik
    Verslype, Chris
    ONKOLOGIE, 2011, 34 (07): : 368 - 376
  • [25] Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma
    Zhao, Chang
    Pei, Shenglin
    Chen, Zuyi
    Ma, Yilong
    JOURNAL OF BUON, 2019, 24 (03): : 1150 - 1166
  • [26] Acute Eosinophilic and Neutrophilic Pneumonia following Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin for Hepatocellular Carcinoma: A Case Report
    Alifakioti, Dimitra
    Daccord, Cecile
    Lachenal, Yann
    Fitting, Jean-William
    RESPIRATION, 2014, 88 (05) : 426 - 429
  • [27] Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients
    Zhou, Guan-Hui
    Han, Jun
    Sun, Jun-Hui
    Zhang, Yue-Lin
    Zhou, Tan-Yang
    Nie, Chun-Hui
    Zhu, Tong-Yin
    Chen, Sheng-Qun
    Wang, Bao-Quan
    Yu, Zi-Niu
    Wang, Hong-Liang
    Chen, Li-Ming
    Wang, Wei-Lin
    Zheng, Shu-Sen
    BMC CANCER, 2018, 18
  • [28] Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma
    Liu, Yi-Sheng
    Ou, Ming-Ching
    Tsai, Yi-Shan
    Lin, Xi-Zhang
    Wang, Chien-Kuo
    Tsai, Hong-Ming
    Chuang, Ming-Tsung
    KOREAN JOURNAL OF RADIOLOGY, 2015, 16 (01) : 125 - 132
  • [30] Comparison of CalliSpheres(R) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial
    Shi, Zhongxing
    Wang, Dongqing
    Kang, Tanrong
    Yi, Ru
    Cui, Liming
    Jiang, Huijie
    RADIOLOGY AND ONCOLOGY, 2023, 57 (01) : 70 - 79